-+ 0.00%
-+ 0.00%
-+ 0.00%

On September 14, Genmai Biotech announced the completion of Series D financing of nearly 600 million yuan. This round of financing was co-led by Shanghai International Group Investment Co., Ltd., Shenzhen Venture Capital, Shengwei Rongquan Fund, and Guoxin Fund. Old shareholders such as Hunan Financial and Credit Industry Fund, Xiangjiang SDIC, Guosheng Hongyuan, German Union Capital, Shenzhen Hi-Tech Investment, Vojie Capital, Shuangye Venture Capital, and Renxian Capital continued to increase. The financing will be used for the company's technological innovation, industrial delivery and global market expansion in the field of biomics.

Zhitongcaijing·09/14/2026 00:41:08
Listen to the news
On September 14, Genmai Biotech announced the completion of Series D financing of nearly 600 million yuan. This round of financing was co-led by Shanghai International Group Investment Co., Ltd., Shenzhen Venture Capital, Shengwei Rongquan Fund, and Guoxin Fund. Old shareholders such as Hunan Financial and Credit Industry Fund, Xiangjiang SDIC, Guosheng Hongyuan, German Union Capital, Shenzhen Hi-Tech Investment, Vojie Capital, Shuangye Venture Capital, and Renxian Capital continued to increase. The financing will be used for the company's technological innovation, industrial delivery and global market expansion in the field of biomics.